{"prompt": "['MC1575', '24', 'Amendment 2', '8.0', 'DOSAGE MODIFICATIONS', 'Strictly follow the modifications in Table 8.1 for the first two cycles, until individual treatment', 'tolerance can be ascertained. Thereafter, these modifications should be regarded as guidelines to', 'produce mild-to-moderate, but not debilitating, side effects. If multiple adverse events are seen,', 'administer dose based on greatest reduction required for any single adverse event observed.', 'Reductions or increases apply to treatment given in the preceding cycle and are based on adverse', 'events observed since the prior dose.', '8.1', 'Dose Modification Table', 'If patient is able to tolerate the starting dose of 20 mg daily for the first 2 cycles and if', 'patient shows stable disease (SD) or objective response (OR) by RECIST 1.1 (see Section', \"11.0), then dose can be escalated to 24 mg daily at the physician's discretion.\", 'Otherwise follow the dose modifications below:', 'Dose', 'Level', 'Lenvatinib', '+1', '24 mg daily', '0*', '20 mg daily', '-1', '14 mg daily', '-2', '10 mg daily', '*Dose level 0 refers to the starting dose.', 'ALERT: ADR reporting may be required for some adverse events (See Section 10.0)', '8.2', 'Dose Modifications Based on Adverse Events', 'CTCAE', 'System/Organ/Class', '(SOC)', 'ADVERSE EVENT', 'AGENT', 'ACTION**', 'Hold treatment until event is Grade 2;', 'reduce one dose level', 'Blood and lymphatic', 'Anemia*', 'If no recovery to Grade 2 or recurrent', 'lenvatinib', 'system', 'Grade >3', 'Grade 3 or 4, discontinue lenvatinib and', 'enter event monitoring. However, if the', 'subject is benefiting from therapy, contact', 'the PI to discuss course of action.', 'Acute coronary', 'Discontinue lenvatinib and enter event', 'Cardiac disorders', 'syndrome', 'Grade >3', 'monitoring', 'Grade 3, hold lenvatinib until it resolves', 'to Grade 1 or less and resume at one', 'Gastrointestinal', 'Diarrhea', 'reduced dose level', 'disorders', 'Grade >3', 'Grade 4, discontinue lenvatinib and enter', 'event monitoring', 'Grade 3, hold lenvatinib until it resolves', 'Nausea/vomiting', 'to Grade 1 or less and resume at one', 'Grade >3 despite', 'reduced dose level', 'antiemetics', 'Grade 4, discontinue lenvatinib and enter', 'event monitoring', 'Protocol Version Date:16Aug2018']['MC1575', '25', 'Amendment 2', 'CTCAE', 'System/Organ/Class', '(SOC)', 'ADVERSE EVENT', 'AGENT', 'ACTION*', 'Discontinue lenvatinib and enter event', 'Gastrointestinal', 'Weight loss', 'monitoring', 'disorders', 'Grade >3', 'However, if the subject is benefiting from', 'therapy, contact the PI to discuss course of', 'action', 'Grade 2, hold lenvatinib until it resolves', 'General disorders and', 'to Grade 1 or less and resume at one', 'administration site', 'Fatigue', 'reduced dose level', 'Grade >2', 'conditions', 'Grade 3, discontinue lenvatinib and enter', 'event monitoring', 'Grade 3 and 4, hold lenvatinib and replace', 'Endocrine disorders', 'Hypothyroidism', 'with levothyroxine until TSH is', 'Grade >3', 'normalized and resume lenvatinib at same', 'dose', 'Hold treatment until event is Grade 2;', 'reduce one dose level', 'Neutrophil count', 'If no recovery to <Grade 2 or recurrent', 'Investigations', 'decreased', 'lenvatinib', 'Grade 3 or 4, discontinue lenvatinib and', 'Grade >3', 'enter event monitoring', 'However, if the subject is benefiting from', 'therapy, contact the PI to discuss course of', 'action', 'Hold treatment until event is Grade 2;', 'reduce one dose level', 'If no recovery to <Grade 2 or recurrent', 'Platelet count decreased', 'Grade 3 or 4, discontinue lenvatinib and', 'Grade >3', 'enter event monitoring', 'However, if the subject is benefiting from', 'therapy, contact the PI to discuss course of', 'action', 'Infections and', 'Any infection', 'Hold lenvatinib; resume when AE is', 'infestations', 'Grade >3', 'Grade 1 or less', 'Metabolism and', 'Hold lenvatinib until it resolves and', 'nutrition disorders', 'Tumor lysis Grade >3', 'resume at one reduced dose level', 'Grade 3, hold lenvatinib until it resolves', 'to Grade 2 or less and resume at one', 'Renal and urinary', 'Proteinuria Grade >3', 'reduced dose level (see Section 8.33)', 'disorders', 'Grade 4, discontinue lenvatinib and enter', 'event monitoring', 'Grade 2, hold lenvatinib until it resolves', 'Skin and subcutaneous', 'Palmoplantar', 'to Grade 1 or less and resume at one', 'tissue disorders', 'erythrodysesthesia', 'reduced dose level', 'Grade >2', 'Grade 3, discontinue lenvatinib and enter', 'event monitoring', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}